NCT04362748

Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

CompletedPHASE1INTERVENTIONAL

Trial Details

Start: 2020-09-15Est. Completion: 2023-09-21

Enrollment target: 34 participants

Locations

City of Hope National Medical Center, Duarte, California, United States
Indiana University, Indianapolis, Indiana, United States
Washington University, St Louis, Missouri, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
St Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia
Monash Medical Centre, Clayton, Victoria, Australia
Cliniques Universitaires Saint Luc, Brussels, Belgium
Universitair Ziekenhuis Gent, Ghent, Belgium
Hospital Universitari Vall d Hebron, Barcelona, Catalonia, Spain
Hospital Clinic i Provincial de Barcelona, Barcelona, Catalonia, Spain

Other microbiome trials you might be interested in

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerPhase 2Recruiting

Recurrent Breast CarcinomaStage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7

This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treat…

Mobile, United StatesEst. completion Nov 6, 2020

View Trial →

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)Phase 3Recruiting

Non-small Cell Lung Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.